市场调查报告书
商品编码
1465050
暴食症市场:按产品、最终用户划分 - 2024-2030 年全球预测Binge Eating Disorder Market by Product (Diagnostics, Treatments), End-User (Hospitals, Specialty Clinics) - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
暴食症市场规模预计2023年为5.5642亿美元,2024年达到5.8785亿美元,预计2030年将达到8.3576亿美元,复合年增长率为5.98%。
暴食症(BED)被认为是饮食障碍,其特征是经常在短时间内反覆摄入大量食物,在暴食期间感到失控,随后感到羞耻,痛苦等,体验内疚。暴食的频率和严重程度各不相同,被归类为一种需要引起注意的严重心理健康状况。人们越来越意识到和理解暴食症是一个严重的健康问题,越来越多的人正在寻求治疗。此外,包括认知行为疗法(CBT)、药物疗法和个人化治疗在内的治疗方案的进步为管理提供了有效的手段,并成为暴食症市场的关键驱动因素。儘管有成长的希望,但缺乏对心理健康和饮食障碍的认识和耻辱阻碍了人们寻求治疗。此外,某些地区高昂的治疗费用和缺乏保险覆盖对获得有效治疗方法构成了重大障碍。然而,将远端医疗服务和用于自我管理的行动应用程式等先进技术整合到护理过程中,为偏远和服务欠缺地区的患者提供了新的帮助方法。此外,持续的研究和开发正在产生新的治疗药物和治疗性介入,扩大了可用治疗选择的范围。
主要市场统计 | |
---|---|
基准年[2023] | 55642万美元 |
预测年份 [2024] | 58785万美元 |
预测年份 [2030] | 83576万美元 |
复合年增长率(%) | 5.98% |
需要有效的诊断来准确识别产品 BED 和合併症
暴食症诊断领域主要涉及心理评估、身体检查和实验室检查。准确和早期的诊断工具对于了解患者的饮食行为、病史和心理健康状况至关重要。
暴食症的治疗包括药物治疗、心理治疗和支持团体/咨询。托吡酯等抗惊厥药物可以透过调节大脑中的神经传递途径来稳定情绪并可能降低食慾。抗忧郁症,包括选择性血清素再回收抑制剂(SSRI),通常用于治疗暴食症,反映了暴食症和情绪障碍的共病。理论上,抗忧郁症药物治疗暴饮暴食的有效性源于其提高血清素水平、影响情绪并可能减少强迫性饮食行为的能力。认知行为疗法(CBT)专注于识别和改变与暴饮暴食相关的负面思维模式和行为。 CBT 帮助人们制定应对策略,以控制暴饮暴食的衝动,提高自尊,并处理同时发生的心理问题,例如忧郁症和焦虑。辩证行为疗法(DBT)是认知行为疗法的一种型态,它整合了正念、情绪调节、痛苦承受和人际互动有效性的策略。 DBT 在 BED 治疗中的主要重点是帮助个人理解和接受他们的暴食行为,同时努力透过培养应对技能来改变这些行为。人际心理治疗(IPT)是一种限时治疗方法,专注于改善人际功能和沟通技巧。探讨可能引发暴食事件的潜在人际问题,例如未解决的悲伤、角色衝突、角色转换和人际沟通缺陷。
最终使用者:对于能够提供满足 BED 患者复杂需求所需的综合服务的医院,人们的偏好较高。
医院在暴食症(BED)的治疗和管理中发挥重要作用。最终使用者医院采用多学科方法提供全面的护理,包括医学评估、营养咨询、精神支持和行为治疗。医院是首选,因为它们有能力提供即时医疗护理和后续治疗计划。专门治疗饮食障碍的专业诊所为暴食症患者提供有针对性的个人化照护。这些诊所提供各种专业治疗方法,包括认知行为疗法 (CBT)、人际心理治疗 (IPT)、辩证行为疗法 (DBT) 和 BED 特定药物管理。这些诊所的专业性使人们能够更深入地了解饮食障碍,并创造一个让患者接受饮食障碍治疗经验丰富的专业人员的重症监护的环境。
区域洞察
在美洲,人们对暴食症的认识和诊断不断提高,导致药物和非药物治疗的大量采用,从而导致该地区的市场表现强劲。 FDA 对 BED 专用药物的核准以及保险公司对治疗疗程的保险覆盖正在促进成长。在 EMEA(欧洲、中东和非洲)地区,人们越来越认识到暴食症是一种独特的医疗状况,这正在影响市场表现。欧洲拥有先进的医疗保健系统和认知行为疗法 (CBT) 等广泛的治疗选择,是欧洲、中东和非洲地区暴食症市场成长的主要贡献者。另一方面,由于意识和医疗基础设施有限,中东和非洲地区的成长正在放缓。在亚太地区,由于人们对心理健康的认识不断提高,人们对暴食症的认识及其治疗市场正在逐渐扩大。然而,该地区面临心理健康文化耻辱和缺乏专业医疗保健提供者等挑战。
FPNV定位矩阵
FPNV 定位矩阵对于评估暴食症市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对暴食症市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.暴食症市场的市场规模和预测是多少?
2.在暴食症市场预测期间内,有哪些产品、细分市场、应用和领域需要考虑投资?
3. 暴食症市场的技术趋势和法规结构是什么?
4.暴食症市场主要供应商的市场占有率是多少?
5. 进入暴食症市场的合适型态和策略手段是什么?
[187 Pages Report] The Binge Eating Disorder Market size was estimated at USD 556.42 million in 2023 and expected to reach USD 587.85 million in 2024, at a CAGR 5.98% to reach USD 835.76 million by 2030.
Binge eating disorder (BED) is recognized as an eating disorder described by recurrent episodes of consuming large quantities of food, often quickly, accompanied by a feeling of loss of control during the bingeing and experiencing shame, distress, or guilt afterward. It differs from overeating in its frequency and severity, and it's classified as a significant mental health condition requiring attention. A growing awareness and understanding of BED as a significant health issue have led to more people seeking treatment. Additionally, advancements in treatment options, including cognitive behavioral therapy (CBT), medications, and personalized therapy sessions, have provided effective means for management, acting as a significant driver for the binge eating disorder market. Despite the growth prospects, a lack of awareness and the stigma associated with mental health and eating disorders hinders individuals from seeking treatment. Moreover, the high cost of therapy and lack of insurance coverage in some areas pose significant barriers to accessing effective treatment options. However, the integration of advanced technology in treatment processes, such as telehealth services and mobile applications for self-management, offers new ways to support individuals in remote or underserved locations. Additionally, ongoing research and development are leading to novel therapeutic drugs and interventions, expanding the range of treatment options available.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 556.42 million |
Estimated Year [2024] | USD 587.85 million |
Forecast Year [2030] | USD 835.76 million |
CAGR (%) | 5.98% |
Product: Need for efficient diagnosis to accurately identify BED and any comorbid conditions
The diagnostics segment for binge eating disorder primarily involves psychological evaluations, physical exams, and laboratory tests. Accurate and early diagnostic tools are crucial for understanding the patient's eating behaviors, history, and mental health status.
The treatment segment for binge eating disorder comprises pharmacotherapy, psychotherapy, and support groups/counseling. Anticonvulsants, such as topiramate, stabilize mood and possibly reduce food cravings through modulation of neurotransmitter pathways in the brain. Antidepressants, including selective serotonin reuptake inhibitors (SSRIs), are commonly used in the treatment of BED, reflecting the comorbidity of BED with mood disorders. The effectiveness of antidepressants in treating BED is theorized to come from their ability to increase serotonin levels, which may influence mood and potentially reduce compulsive eating behaviors. Cognitive behavioral therapy (CBT) focuses on identifying and changing negative thought patterns and behaviors related to binge eating. CBT helps individuals develop coping strategies to control urges to binge, improve self-esteem, and address co-occurring psychological issues such as depression or anxiety. Dialectical behavior therapy (DBT) is a form of cognitive-behavioral therapy that integrates strategies for mindfulness, emotion regulation, distress tolerance, and interpersonal effectiveness. Its primary focus in BED treatment is helping individuals understand and accept their binge-eating behaviors while simultaneously working on changing these behaviors by building coping skills. Interpersonal psychotherapy (IPT) is a time-limited treatment focused on improving interpersonal functioning and communication skills. It explores underlying interpersonal issues that may trigger binge eating episodes, such as unresolved grief, role disputes, role transitions, and interpersonal deficits.
End-User: Higher preferences for hospitals with comprehensive services, essential for addressing the complex needs of BED patients
Hospitals have a crucial role in the treatment and management of binge eating disorder (BED). As end-users, hospitals adopt a multidisciplinary approach to provide comprehensive care, including medical evaluation, nutritional counseling, psychiatric support, and behavioral therapies. Hospitals are preferred for their capacity to offer immediate medical care combined with follow-up treatment plans. Specialty clinics focused on eating disorders offer targeted and personalized care for individuals with binge eating disorders. These clinics provide an array of specialized treatment options, including cognitive-behavioral therapy (CBT), interpersonal psychotherapy (IPT), dialectical behavior therapy (DBT), and medication management tailored specifically to BED. The specialized nature of these clinics allows for a deeper understanding of the disorder, fostering an environment where patients can receive focused care from professionals highly experienced in treating eating disorders.
Regional Insights
In the Americas, increasing awareness and diagnosis of binge eating disorder has resulted in significant adoption of both pharmacological and non-pharmacological treatments, which has led to a robust market performance in this region. The FDA's approval of medications specific to BED and coverage of therapy sessions by insurance companies contribute to the growth. In the EMEA region, the market performance is influenced by a growing awareness of BED as a distinct medical condition. Europe, with advanced healthcare systems and widespread availability of treatment options, including cognitive behavioral therapy (CBT), has been contributing majorly to the growth of EMEA's binge eating disorder market. The Middle East and Africa, however, exhibit slower growth owing to limited awareness and healthcare infrastructure. The APAC region is witnessing a gradual increase in the recognition of binge eating disorder and its treatment market, driven by the rise of mental health awareness. However, the region faces challenges such as cultural stigmas around mental health and a paucity of specialized healthcare providers.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Binge Eating Disorder Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Binge Eating Disorder Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Binge Eating Disorder Market, highlighting leading vendors and their innovative profiles. These include Alsana, Inc., Alvogen, Amneal Pharmaceuticals, Inc., Apotex Inc., Ascent Pharmaceuticals, Inc., BALANCE Eating Disorder Treatment Center, Carolina House Eating Disorder Treatment Center, Center for Change, Eating Disorders Treatment Center, Eating Recovery Center, Equip Health Medical, P.C., Hikma Pharmaceuticals PLC, Mallinckrodt PLC, Monte Nido & Affiliates Holdings, LLC, Montecatini Eating Disorder Treatment Center, Natural Food Therapy, Red Oak Recovery, Rhodes Pharmaceuticals L.P. by Purdue Pharma L.P., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, TalktoAngel, The London Centre for Eating Disorders and Body Image Ltd., Timberline Knolls Residential Treatment Center, Veritas Collaborative, and Viatris Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Binge Eating Disorder Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Binge Eating Disorder Market?
3. What are the technology trends and regulatory frameworks in the Binge Eating Disorder Market?
4. What is the market share of the leading vendors in the Binge Eating Disorder Market?
5. Which modes and strategic moves are suitable for entering the Binge Eating Disorder Market?
T